Puma Biotechnology, Inc. (PBYI) Research
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Market snapshot
- Symbol
- PBYI
- Price
- $7.56
- Day change
- +4.56%
- Market cap
- $384.8M
- P/E ratio
- 15.76x
- 52-week range
- 3.03-7.9
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Recent news
- Gun Makers Reach Cooperation Pact After Months of Tense Proxy Battle
Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to 25% of outstanding shares, including a tender offer at a minimum of $44.80 a share.
Peer companies
Recent insider activity
- WILSON TROY EDWARD — A-Award (27000 shares) on 2026-06-11
- WILSON TROY EDWARD — S-Sale (10800 shares) on 2026-06-12
- Stuglik Brian M — A-Award (27000 shares) on 2026-06-11
- Stuglik Brian M — S-Sale (8100 shares) on 2026-06-12
- Senderowicz Adrian — A-Award (27000 shares) on 2026-06-11
Open Puma Biotechnology, Inc. (PBYI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.